2023 Q4 Form 10-Q Financial Statement

#000149315223040626 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $391.0K $239.0K $0.00
YoY Change
Cost Of Revenue $748.0K $432.0K $179.0K
YoY Change 1000.0% 141.34%
Gross Profit -$356.0K -$193.0K -$179.0K
YoY Change 423.53% 7.82%
Gross Profit Margin -91.05% -80.75%
Selling, General & Admin $9.768M $10.21M $7.990M
YoY Change 9.25% 27.78% 135.35%
% of Gross Profit
Research & Development $6.838M $7.130M $4.452M
YoY Change 36.76% 60.15% 58.6%
% of Gross Profit
Depreciation & Amortization $559.0K $420.0K $147.0K
YoY Change 118.36% 185.71% 98.33%
% of Gross Profit
Operating Expenses $16.61M $17.34M $12.44M
YoY Change 19.12% 39.38% 100.65%
Operating Profit -$16.96M -$17.54M -$12.62M
YoY Change 21.08% 38.94%
Interest Expense $919.0K $914.0K -$265.0K
YoY Change 1897.83% -444.91% 65.63%
% of Operating Profit
Other Income/Expense, Net -$294.0K $88.00K
YoY Change -239.34%
Pretax Income -$17.26M -$17.43M -$12.80M
YoY Change 25.06% 36.19% 47.26%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$16.22M -$16.22M -$11.97M
YoY Change 27.25% 35.53% 37.71%
Net Earnings / Revenue -4148.34% -6786.61%
Basic Earnings Per Share -$0.50 -$0.51 -$0.40
Diluted Earnings Per Share -$0.50 -$0.51 -$400.3K
COMMON SHARES
Basic Shares Outstanding 31.97M shares 31.71M shares 29.89M shares
Diluted Shares Outstanding 32.46M shares 31.80M shares 29.90M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.26M $38.64M $62.45M
YoY Change -41.15% -38.12% 30.92%
Cash & Equivalents $7.971M $13.18M $29.83M
Short-Term Investments $23.29M $25.46M $32.62M
Other Short-Term Assets $6.349M $6.490M $11.51M
YoY Change -44.13% -43.6% 353.03%
Inventory $1.533M $1.574M $711.0K
Prepaid Expenses
Receivables $294.0K $205.0K
Other Receivables $0.00 $220.0K
Total Short-Term Assets $39.44M $47.13M $75.08M
YoY Change -40.26% -37.22% 49.28%
LONG-TERM ASSETS
Property, Plant & Equipment $8.551M $6.824M $5.022M
YoY Change 135.95% 35.88% 57.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $213.0K $224.0K $205.0K
YoY Change 0.95% 9.27% -3.3%
Total Long-Term Assets $12.47M $10.87M $6.961M
YoY Change 57.0% 56.17% 85.08%
TOTAL ASSETS
Total Short-Term Assets $39.44M $47.13M $75.08M
Total Long-Term Assets $12.47M $10.87M $6.961M
Total Assets $51.91M $58.01M $82.04M
YoY Change -29.81% -29.3% 51.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.220M $3.292M $2.006M
YoY Change 128.21% 64.11% -10.49%
Accrued Expenses $7.882M $8.496M $9.282M
YoY Change -19.38% -8.47% 104.9%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $310.0K
YoY Change -100.0% -100.0% 121.43%
Long-Term Debt Due $130.0K $280.0K
YoY Change
Total Short-Term Liabilities $11.64M $12.45M $11.60M
YoY Change 0.38% 7.38% 67.8%
LONG-TERM LIABILITIES
Long-Term Debt $14.38M $14.04M $200.0K
YoY Change 10171.43% 6920.0% -95.59%
Other Long-Term Liabilities $6.589M
YoY Change 291.27%
Total Long-Term Liabilities $0.00 $0.00 $6.789M
YoY Change -100.0% -100.0% 9.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.64M $12.45M $11.60M
Total Long-Term Liabilities $0.00 $0.00 $6.789M
Total Liabilities $28.44M $29.17M $23.23M
YoY Change 53.57% 25.56% 76.89%
SHAREHOLDERS EQUITY
Retained Earnings -$226.0M -$209.8M
YoY Change 41.87%
Common Stock $4.000K $3.000K
YoY Change 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost) $25.00K $25.00K
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity $20.81M $25.75M $58.81M
YoY Change
Total Liabilities & Shareholders Equity $51.91M $58.01M $82.04M
YoY Change -29.81% -29.3% 51.77%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$16.22M -$16.22M -$11.97M
YoY Change 27.25% 35.53% 37.71%
Depreciation, Depletion And Amortization $559.0K $420.0K $147.0K
YoY Change 118.36% 185.71% 98.33%
Cash From Operating Activities -$13.82M -$14.32M -$9.220M
YoY Change 62.39% 55.31% 85.15%
INVESTING ACTIVITIES
Capital Expenditures $1.334M $1.680M -$963.0K
YoY Change 110.41% -274.45% 62.69%
Acquisitions
YoY Change
Other Investing Activities $2.186M -$80.00K -$32.61M
YoY Change -56.47% -99.75% 44568.49%
Cash From Investing Activities $852.0K -$1.770M -$33.57M
YoY Change -80.58% -94.73% 4948.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.234M 470.0K 133.0K
YoY Change -1788.39% 253.38% -99.1%
NET CHANGE
Cash From Operating Activities -13.82M -14.32M -9.220M
Cash From Investing Activities 852.0K -1.770M -33.57M
Cash From Financing Activities 5.234M 470.0K 133.0K
Net Change In Cash -7.733M -15.62M -42.66M
YoY Change 74.48% -63.38% -567.86%
FREE CASH FLOW
Cash From Operating Activities -$13.82M -$14.32M -$9.220M
Capital Expenditures $1.334M $1.680M -$963.0K
Free Cash Flow -$15.15M -$16.00M -$8.257M
YoY Change 65.72% 93.77% 88.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity Central Index Key
EntityCentralIndexKey
0001641631
CY2023Q1 XAIR Bifurcated Derivative
BifurcatedDerivative
usd
XAIR Dividend Income Loss Operating
DividendIncomeLossOperating
usd
CY2022Q3 XAIR Estimated Liability For Contingent Loss
EstimatedLiabilityForContingentLoss
usd
XAIR Estimated Liability For Contingent Loss
EstimatedLiabilityForContingentLoss
usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
usd
XAIR Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
usd
XAIR Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
usd
XAIR Payment For Proceeds From Sale And Maturity Of Marketable Securities
PaymentForProceedsFromSaleAndMaturityOfMarketableSecurities
usd
XAIR Payments To Security Deposits Made On Operating Leases
PaymentsToSecurityDepositsMadeOnOperatingLeases
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
usd
XAIR Debt Discount
DebtDiscount
usd
XAIR End Of Term Loan Liability
EndOfTermLoanLiability
usd
XAIR Warrant Liabilities
WarrantLiabilities
usd
XAIR Derivatives Liability
DerivativesLiability
usd
XAIR Rightofuse Assets
RightofuseAssets
usd
XAIR Operating Lease Liabilities
OperatingLeaseLiabilities
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
usd
CY2023Q1 XAIR Goods Received Not Invoiced
GoodsReceivedNotInvoiced
usd
CY2023Q3 XAIR Accrued Circassia Settlement Long Term
AccruedCircassiaSettlementLongTerm
usd
CY2023Q3 us-gaap Other Long Term Debt
OtherLongTermDebt
usd
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
shares
CY2023Q2 XAIR Amortization Of Debt Discount
AmortizationOfDebtDiscount
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38892
dei Entity Registrant Name
EntityRegistrantName
BEYOND AIR, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3812456
dei Entity Address Address Line1
EntityAddressAddressLine1
900 Stewart Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 301
CY2023Q3 us-gaap Loans Payable Current
LoansPayableCurrent
275000 usd
CY2023Q1 us-gaap Loans Payable Current
LoansPayableCurrent
775000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12454000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
19780000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2087000 usd
dei Entity Address City Or Town
EntityAddressCityOrTown
Garden City
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11530
dei City Area Code
CityAreaCode
516
dei Local Phone Number
LocalPhoneNumber
665-8200
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
XAIR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31972434 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13179000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29158000 usd
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
25463000 usd
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
16724000 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
5231000 usd
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
10129000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
205000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
1574000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
1129000 usd
CY2023Q1 us-gaap Grants Receivable
GrantsReceivable
420000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1481000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1850000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
47134000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
59410000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1529000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1632000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2294000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2493000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6824000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5003000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
224000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
212000 usd
CY2023Q3 us-gaap Assets
Assets
58005000 usd
CY2023Q1 us-gaap Assets
Assets
68749000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3292000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2016000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8496000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16613000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
391000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
376000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2321000 usd
CY2023Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
14044000 usd
CY2023Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
120000 usd
CY2023Q3 XAIR Warrant Liability
WarrantLiability
238000 usd
CY2023Q3 XAIR Bifurcated Derivative
BifurcatedDerivative
349000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4500000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
29173000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
26721000 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31972434 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31972434 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30738585 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30738585 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
25000 usd
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
25000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
235495000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
217339000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-209770000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179455000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
43000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
53000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
25746000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
37915000 usd
CY2023Q3 us-gaap Minority Interest
MinorityInterest
3085000 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
4113000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
28831000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
42028000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58005000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68749000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
239000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
298000 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
432000 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
179000 usd
us-gaap Cost Of Revenue
CostOfRevenue
735000 usd
us-gaap Cost Of Revenue
CostOfRevenue
179000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
-193000 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
-179000 usd
us-gaap Gross Profit
GrossProfit
-437000 usd
us-gaap Gross Profit
GrossProfit
-179000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7130000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4452000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11826000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7678000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10211000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7990000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21147000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16203000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
17342000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
12442000 usd
us-gaap Operating Expenses
OperatingExpenses
32972000 usd
us-gaap Operating Expenses
OperatingExpenses
23882000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17535000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12621000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-33410000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-24061000 usd
CY2023Q3 XAIR Dividend Income Loss Operating
DividendIncomeLossOperating
641000 usd
XAIR Dividend Income Loss Operating
DividendIncomeLossOperating
1050000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
914000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
48000 usd
us-gaap Interest Expense
InterestExpense
1072000 usd
us-gaap Interest Expense
InterestExpense
96000 usd
CY2023Q3 XAIR Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
324000 usd
XAIR Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
647000 usd
CY2023Q3 XAIR Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
500000 usd
XAIR Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
1012000 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-42000 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-217000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-34000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-394000 usd
CY2023Q3 XAIR Estimated Liability For Contingent Loss
EstimatedLiabilityForContingentLoss
-400000 usd
XAIR Estimated Liability For Contingent Loss
EstimatedLiabilityForContingentLoss
-598000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
88000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-77000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
99000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
109000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-177000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
929000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-391000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-17426000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-12797000 usd
us-gaap Profit Loss
ProfitLoss
-32481000 usd
us-gaap Profit Loss
ProfitLoss
-24452000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1205000 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-830000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2165000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1550000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16220000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11968000 usd
us-gaap Net Income Loss
NetIncomeLoss
-30315000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22902000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-35000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
171000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-9000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
343000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16255000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11797000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30325000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22559000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31800492 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31800492 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29898825 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29898825 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31592880 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31592880 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29893414 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29893414 shares
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
42028000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
217000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5813000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6115000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
25000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-15055000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
39143000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
39143000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
688000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6460000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-35000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-17426000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
28831000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
78209000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4624000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
172000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-11654000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71351000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71351000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71351000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
214000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4714000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
171000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-12797000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
63652000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
63652000 usd
us-gaap Profit Loss
ProfitLoss
-32481000 usd
us-gaap Profit Loss
ProfitLoss
-24452000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
682000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
235000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
102000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
102000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12575000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
9338000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
413000 usd
XAIR Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
647000 usd
XAIR Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
1012000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
175000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
138000 usd
XAIR Foreign Currency Adjustments
ForeignCurrencyAdjustments
1000 usd
XAIR Foreign Currency Adjustments
ForeignCurrencyAdjustments
394000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
235000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-105000 usd
us-gaap Provision For Other Losses
ProvisionForOtherLosses
61000 usd
us-gaap Provision For Other Losses
ProvisionForOtherLosses
49000 usd
XAIR Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
-420000 usd
XAIR Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
-87000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
505000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
363000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
205000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-367000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-421000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1277000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
864000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-12605000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-3108000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-194000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31472000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16059000 usd
XAIR Proceed From Payments To Acquire Marketable Securities
ProceedFromPaymentsToAcquireMarketableSecurities
55213000 usd
XAIR Proceed From Payments To Acquire Marketable Securities
ProceedFromPaymentsToAcquireMarketableSecurities
32617000 usd
XAIR Payment For Proceeds From Sale And Maturity Of Marketable Securities
PaymentForProceedsFromSaleAndMaturityOfMarketableSecurities
-46269000 usd
XAIR Payments To Security Deposits Made On Operating Leases
PaymentsToSecurityDepositsMadeOnOperatingLeases
-2000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2477000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1221000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11421000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33835000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6501000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
214000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
217000 usd
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
15817000 usd
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
500000 usd
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
617000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22036000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-403000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-19000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20876000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-50296000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39287000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
90230000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18410000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39934000 usd
XAIR Debt Discount
DebtDiscount
4541000 usd
XAIR End Of Term Loan Liability
EndOfTermLoanLiability
-613000 usd
XAIR Warrant Liabilities
WarrantLiabilities
885000 usd
XAIR Derivatives Liability
DerivativesLiability
-1361000 usd
XAIR Rightofuse Assets
RightofuseAssets
274000 usd
XAIR Operating Lease Liabilities
OperatingLeaseLiabilities
274000 usd
us-gaap Interest Paid Net
InterestPaidNet
369000 usd
us-gaap Interest Paid Net
InterestPaidNet
16000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
64000 usd
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
16724000 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_844_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zOOAy0fS8599" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zGNI5VbHw5U6">Reclassifications</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_848_eus-gaap--UseOfEstimates_zgxUNgUSUHKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zoQ8zGtgJGIl">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its significant estimates including accruals for expenses under consulting, licensing agreements, and clinical trials, stock-based compensation, contingency recognition and the determination of deferred tax attributes and the valuation allowance thereon.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31500000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-209800000 usd
CY2023Q3 XAIR Cash And Cash Equivalents And Marketable Securities
CashAndCashEquivalentsAndMarketableSecurities
38600000 usd
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
25463000 usd
CY2023Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
588000 usd
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
16724000 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
43874000 usd
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
56011000 usd
XAIR Warrants Liability
WarrantsLiability
885000 usd
XAIR Derivative Liability
DerivativeLiability
1361000 usd
XAIR Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
647000 usd
XAIR Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
1012000 usd
CY2023Q3 XAIR Warrant Liability
WarrantLiability
238000 usd
CY2023Q3 XAIR Bifurcated Derivative
BifurcatedDerivative
349000 usd
XAIR Decline In Restricted Cash
DeclineInRestrictedCash
4900000 usd
XAIR Incremental Amount
IncrementalAmount
2500000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13179000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29158000 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
5231000 usd
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
10129000 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
18410000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
39287000 usd
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
25463000 usd
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
25463000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-105000 usd
CY2023Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zM9bgmrxzDCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zQE4ZQC6oiM5">Supplier Concentration</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company relies on third-party suppliers to provide materials for its devices and consumables.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the three months ended September 30, 2023, the Company purchased approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoThirdPartyVendorsMember_zHUjU6jrqUQd" title="Concentration risk percentage">88</span>% of its materials from two third-party vendors, with these vendors representing <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorOneMember_zvWZihIL25zb" title="Concentration risk percentage">80</span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorTwoMember_zyKc7cwRr2L5" title="Concentration risk percentage">8</span>%, respectively. In the three months ended September 30, 2022, the Company purchased approximately <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoThirdPartyVendorsMember_zvnJSheVs80k" title="Concentration risk percentage">80</span>% of its materials from two third-party vendors, with these vendors representing <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorOneMember_zOeH3WVqX6Jg" title="Concentration risk percentage">59</span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorTwoMember_z5hCc4wzm9zh" title="Concentration risk percentage">21</span>%, respectively. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the six months ended September 30, 2023, the Company purchased approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoThirdPartyVendorsMember_zZhkYrfx5Dyb" title="Concentration risk percentage">86</span>% of its materials from two third-party vendors, with these vendors representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorOneMember_zyZdh01FpCxa" title="Concentration risk percentage">73</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorTwoMember_z6SUivkmRUj1" title="Concentration risk percentage">13</span>%, respectively. In the six months ended September 30, 2022, the Company purchased approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoThirdPartyVendorsMember_zPlk9vghfRx8" title="Concentration risk percentage">69</span>% of its materials from two third-party vendors, with these vendors representing <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorOneMember_zlib8aHUsBtd" title="Concentration risk percentage">53</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorTwoMember_zmmXFkXGrwm7" title="Concentration risk percentage">16</span>%, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8733000 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6256000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1909000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1254000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6824000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5003000 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
200000 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
42500 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1101100 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
6.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.65
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
258000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
184000 usd
CY2023Q3 XAIR Total Shortterm Accrued Expense
TotalShorttermAccruedExpense
8496000 usd
CY2023Q1 XAIR Total Shortterm Accrued Expense
TotalShorttermAccruedExpense
16613000 usd
CY2023Q1 XAIR Accrued Circassia Settlement Long Term
AccruedCircassiaSettlementLongTerm
4500000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
6800 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
5.06
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1095300 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
6.79
CY2023Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
700000 usd
CY2022Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
700000 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1500000 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1400000 usd
XAIR Unrecognized Compensation Cost
UnrecognizedCompensationCost
3600000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
6460000 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
4714000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12575000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
9338000 usd
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
694363 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.02
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1481000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1850000 usd
CY2023Q3 XAIR Vendors Research And Development
VendorsResearchAndDevelopment
1180000 usd
CY2023Q1 XAIR Vendors Research And Development
VendorsResearchAndDevelopment
426000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
581000 usd
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1221000 usd
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1397000 usd
CY2023Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
985000 usd
CY2023Q3 XAIR Contingent Litigation And Settlements
ContingentLitigationAndSettlements
400000 usd
CY2023Q1 XAIR Contingent Litigation And Settlements
ContingentLitigationAndSettlements
10298000 usd
CY2023Q3 XAIR Circassia Settlement Current
CircassiaSettlementCurrent
4500000 usd
CY2023Q1 XAIR Circassia Settlement Current
CircassiaSettlementCurrent
3500000 usd
CY2023Q3 XAIR Goods Received Not Invoiced
GoodsReceivedNotInvoiced
180000 usd
CY2023Q1 us-gaap Other Long Term Debt
OtherLongTermDebt
4500000 usd
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
392465 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10310154 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6991751 shares
CY2022Q3 us-gaap Loss Contingency Accrual Payments
LossContingencyAccrualPayments
2500000 usd
CY2023Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
4500000 usd
CY2023Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
8000000.0 usd
CY2023Q2 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
7600000 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
233843 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.88
CY2023Q2 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
15800000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1750000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
7000000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7000000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
1750000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
17500000 usd
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
17500000 usd
CY2023Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
17500000 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
4541000 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
4541000 usd
CY2023Q3 XAIR Amortization Of Debt Discount
AmortizationOfDebtDiscount
413000 usd
CY2023Q3 XAIR Final Payment Liability
FinalPaymentLiability
613000 usd
CY2023Q2 XAIR Final Payment Liability
FinalPaymentLiability
613000 usd
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
13985000 usd
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
13572000 usd

Files In Submission

Name View Source Status
0001493152-23-040626-index-headers.html Edgar Link pending
0001493152-23-040626-index.html Edgar Link pending
0001493152-23-040626.txt Edgar Link pending
0001493152-23-040626-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
form10-q_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xair-20230930.xsd Edgar Link pending
xair-20230930_cal.xml Edgar Link unprocessable
xair-20230930_def.xml Edgar Link unprocessable
xair-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
xair-20230930_pre.xml Edgar Link unprocessable